Vyvanse Related Published Studies
Well-designed clinical trials related to Vyvanse (Lisdexamfetamine)
Health-related quality of life and functional outcomes from a
randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in
children and adolescents with attention-deficit/hyperactivity disorder. [2014]
A post hoc comparison of the effects of lisdexamfetamine dimesylate and
osmotic-release oral system methylphenidate on symptoms of attention-deficit
hyperactivity disorder in children and adolescents. [2013]
Lisdexamfetamine dimesylate improves processing speed and memory in cognitively
impaired MS patients: a phase II study. [2013]
Dose response effects of lisdexamfetamine dimesylate treatment in adults with
ADHD: an exploratory study. [2012]
Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis. [2011.11.04]
Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD. [2011.10]
Effect of lisdexamfetamine dimesylate on sleep in children with ADHD. [2011.08]
Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity. [2011.06]
Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD. [2011.05]
Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. [2011.03]
Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. [2011]
Prediction of placebo response in 2 clinical trials of lisdexamfetamine
dimesylate for the treatment of ADHD. [2011]
Effect of lisdexamfetamine dimesylate on sleep in children with ADHD. [2011]
Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day. [2010.12.14]
Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. [2010.06.24]
Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. [2010.02]
Randomized, double-blind, placebo-controlled, crossover study of the efficacy and
safety of lisdexamfetamine dimesylate in adults with
attention-deficit/hyperactivity disorder: novel findings using a simulated adult
workplace environment design. [2010]
Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. [2010]
Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. [2009.12]
A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. [2009.06.09]
Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. [2009.06]
Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis. [2008.09]
Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. [2008.09]
Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. [2008.03]
Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. [2007.11.01]
Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. [2007.03]
Well-designed clinical trials possibly related to Vyvanse (Lisdexamfetamine)
Impact of stimulant pharmacotherapy on sleep quality: post hoc analyses of 2 large, double-blind, randomized, placebo-controlled trials. [2011.07]
Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. [2010.08]
Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder. [2008.09]
Other research related to Vyvanse (Lisdexamfetamine)
Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized,
placebo-controlled trial. [2015]
Randomized, double-blind, placebo-controlled, crossover study of the effects of
lisdexamfetamine dimesylate and mixed amphetamine salts on cognition throughout
the day in adults with attention-deficit/hyperactivity disorder. [2014]
Efficacy of lisdexamfetamine dimesylate throughout the day in children and
adolescents with attention-deficit/hyperactivity disorder: results from a
randomized, controlled trial. [2014]
Traumatic brain injury-related attention deficits: treatment outcomes with
lisdexamfetamine dimesylate (Vyvanse). [2014]
A systematic review of the safety of lisdexamfetamine dimesylate. [2014]
An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine
dimesylate and venlafaxine extended-release, administered alone and in
combination, in healthy adults. [2013]
An update on lisdexamfetamine dimesylate for the treatment of attention deficit
hyperactivity disorder. [2013]
Use of lisdexamfetamine dimesylate in treatment of executive functioning deficits
and chronic fatigue syndrome: a double blind, placebo-controlled study. [2013]
Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit
hyperactivity disorder. [2012]
Double-blind, placebo-controlled, crossover study of the efficacy and safety of
lisdexamfetamine dimesylate in college students with ADHD. [2012]
Pharmacokinetics of Lisdexamfetamine Dimesylate After Targeted Gastrointestinal Release or Oral Administration in Healthy Adults. [2011.10.28]
Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. [2011.04]
Lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder in adults with a history of depression or history of substance use disorder. [2011.02]
Physician perception of clinical improvement in children with attention-deficit/hyperactivity disorder: a post hoc comparison of lisdexamfetamine dimesylate and mixed amphetamine salts extended release in a crossover analog classroom study. [2011]
Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study. [2010.12]
Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD. [2010.12]
Focus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry. [2010.11]
Understanding the Effect Size of Lisdexamfetamine Dimesylate for Treating ADHD in Children and Adults. [2010.09.13]
Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults. [2010.09]
Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate? [2010.09]
Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. [2010.09]
Eosinophilic hepatitis in an adolescent during lisdexamfetamine dimesylate treatment for ADHD. [2010.06]
Lisdexamfetamine dimesylate: a prodrug stimulant for the treatment of ADHD in children and adults. [2010.05]
Assessing effects of treatment with lisdexamfetamine dimesylate for pediatric ADHD using a parental survey. [2010.04]
Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. [2010.01]
Improvements in executive function correlate with enhanced performance and
functioning and health-related quality of life: evidence from 2 large,
double-blind, randomized, placebo-controlled trials in ADHD. [2010]
Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite,
d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in
children with attention-deficit/hyperactivity disorder: a single-dose,
randomized, open-label, crossover study. [2010]
Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study. [2009.12]
Lisdexamfetamine: a prodrug for the treatment of attention-deficit/hyperactivity disorder. [2009.11.15]
Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder. [2009.10]
Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. [2009.09]
Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder. [2009.08.03]
Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder. [2009.04]
The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. [2009.01]
Lisdexamfetamine dimesylate: in attention-deficit hyperactivity disorder in adults. [2009]
Lisdexamfetamine: a prodrug stimulant for ADHD. [2008.08]
Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. [2008.07.17]
Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. [2008.07]
Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder. [2008.06]
Lisdexamfetamine dimesylate for childhood ADHD. [2008.05]
Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. [2008.01]
Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. [2008]
Toxicity profile of lisdexamfetamine dimesylate in three independent rat toxicology studies. [2007.10]
Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts Extended-Release in Children with ADHD: A Double-Blind, Placebo-Controlled, Crossover Analog Classroom Study. [2007.07.11]
Lisdexamfetamine. [2007]
Other possibly related research studies
Evolution of the treatment of attention-deficit/hyperactivity disorder in children: A review. [2008.05]
Pharmacologic treatment of ADHD: road conditions in driving patients to successful outcomes. [2008.01.08]
The effect of stimulant treatment for ADHD on later substance abuse and the potential for medication misuse, abuse, and diversion. [2007.11]
Gateways to clinical trials. [2008.01]
An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. [2009.06]
Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. [2010]
Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists. [2010.12]
Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder. [2010.12.01]
A pilot study of lis-dexamfetamine dimesylate (LDX/SPD489) to facilitate smoking
cessation in nicotine-dependent adults with ADHD. [2014]
|